TPCera
Immunomodulatory Treatment for Autoimmune Diseases
Company Overview
Snapshot
Founded in May 2016 by Yehuda Shoenfeld, Miri Blank, and Tzachy (Isaac) Tal, TPCera operated with 1–10 employees. In October 2022, TPCera ceased operations.
Business overview
TPCera is a biopharmaceutical company focused on developing immunomodulatory treatments for autoimmune diseases. The company's core technology involves shifting macrophages from an inflammatory (M1) to an anti-inflammatory (M2) state, aiming to modulate conditions such as lupus, colitis, and rheumatoid arthritis. TPCera's lead compound, TPC1022, demonstrated promising preclinical results through subcutaneous and oral administrations in various autoimmune mice models. The company operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Drugs Discovery & Development.
Log in to access full profile ›Company Intelligence Q&A
- What is TPCera's primary focus?
- TPCera develops immunomodulatory compounds designed to shift the immune system from an inflammatory to an anti-inflammatory state, primarily targeting autoimmune diseases.
- Who founded TPCera?
- TPCera was co-founded by Yehuda Shoenfeld, Miri Blank, and Tzachy (Isaac) Tal in May 2016.
- What is the status of TPCera?
- TPCera is currently non-active, having ceased operations in October 2022.
- What is TPCera's lead compound?
- TPCera's lead compound is TPC1022, which has shown promising preclinical results in autoimmune mice models for lupus, colitis, and rheumatoid arthritis.